Form 4: Korro Bio CFO Vineet Agarwal Executes Stock Sales Under 10b5-1 Plan

Vineet Agarwal, CFO of Korro Bio, Inc., sold shares of common stock on October 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 17, 2024, Vineet Agarwal, the Chief Financial Officer of Korro Bio, Inc., executed multiple transactions involving the company's common stock.
• These transactions included the exercise of stock options and the subsequent sale of shares.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 19, 2024.
• Agarwal sold a total of 9,263 shares acquired at $11.68 and 953 shares acquired at $14.98.
• The sales prices ranged from $71.509 to $82.89 per share.
• Following these transactions, Agarwal directly owns 0 shares of Korro Bio, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan suggests that these sales were pre-planned and not based on any inside information at the time of the transactions.

Stakeholder Impact

• The stock sales by a company insider could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price.

Key Dates